Renin-angiotensin-aldosterone system (RAAS) blockers and new antidiabetic agents with cardio- and nephroprotective effects (sodium-glucose cotransporter 2 inhibitors (SGLT2i) - and glucagon-like peptide-1 receptor agonists – (GLP-1 RA)) have drastically changed the prognosis of T2DM patients with kidney disease, reducing cardiovascular events and mortality, slowing the decline of eGFR, and delaying the need for renal replacement therapy (21–23). Here, GLP1R is linked to type 2 diabetes mellitus.